Xlife Sciences AG (SW:XLS) — Stock Price
Xlife Sciences AG (SW:XLS) is currently trading at CHF9.70 CHF, down 5.83% today. Over the past 52 weeks, shares have ranged between CHF9.70 and CHF26.00. This page tracks Xlife Sciences AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Xlife Sciences AG (XLS) total market value.
Xlife Sciences AG (XLS) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Xlife Sciences AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.
Xlife Sciences AG Income Statement — Revenue, Profit & Earnings by Year
Xlife Sciences AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CHF275.31K | CHF834.88K | CHF988.44K | CHF1.03 Million | CHF806.07K |
| Cost of Revenue | CHF265.99K | CHF285.35K | CHF539.42K | CHF842.33K | CHF446.95K |
| Gross Profit | CHF9.32K | CHF549.53K | CHF449.02K | CHF185.64K | CHF359.12K |
| Research & Development | CHF0.00 | CHF15.58K | CHF250.91K | CHF144.72K | CHF228.21K |
| SG&A | CHF1.70 Million | CHF4.19 Million | CHF4.58 Million | CHF5.23 Million | CHF5.37 Million |
| Total Operating Expenses | CHF31.83 Million | CHF20.18 Million | CHF21.30 Million | CHF22.01 Million | CHF6.04 Million |
| Operating Income | CHF-31.56 Million | CHF-19.35 Million | CHF-20.31 Million | CHF-20.98 Million | CHF-5.23 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | CHF448.71K | CHF473.17K | CHF385.03K | CHF687.47K | CHF495.18K |
| Income Before Tax | CHF-31.86 Million | CHF23.97 Million | CHF4.53 Million | CHF4.04 Million | CHF53.19 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CHF-21.55 Million | CHF34.28 Million | CHF14.88 Million | CHF14.31 Million | CHF53.42 Million |
Xlife Sciences AG Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Xlife Sciences AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CHF517.12 Million | CHF540.37 Million | CHF511.99 Million | CHF490.23 Million | CHF480.06 Million |
| Total Current Assets | CHF1.55 Million | CHF14.21 Million | CHF18.12 Million | CHF1.25 Million | CHF2.47 Million |
| Cash & Equivalents | — | CHF99.03K | CHF218.71K | CHF221.04K | CHF1.96 Million |
| Short-term Investments | CHF646.47K | — | — | — | — |
| Net Receivables | CHF93.63K | CHF8.46 Million | CHF9.13 Million | CHF545.21K | CHF483.66K |
| Inventory | CHF29.26K | CHF45.36K | CHF0.00 | — | — |
| Property, Plant & Equipment | — | CHF269.19K | CHF393.67K | CHF535.58K | CHF669.57K |
| Goodwill | — | CHF15.71K | CHF15.71K | — | CHF0.00 |
| Total Liabilities | CHF144.76 Million | CHF235.11 Million | CHF243.82 Million | CHF255.00 Million | CHF268.83 Million |
| Total Current Liabilities | CHF14.93 Million | CHF9.26 Million | CHF5.83 Million | CHF1.93 Million | CHF2.33 Million |
| Long-term Debt | CHF53.37 Million | CHF53.89 Million | CHF55.57 Million | CHF60.24 Million | CHF62.97 Million |
| Net Debt | CHF59.48 Million | CHF59.04 Million | CHF56.20 Million | CHF60.02 Million | CHF61.01 Million |
| Total Stockholder Equity | CHF286.53 Million | CHF305.26 Million | CHF268.17 Million | CHF235.23 Million | CHF211.23 Million |
| Retained Earnings | CHF-21.55 Million | CHF287.67 Million | CHF251.26 Million | CHF229.95 Million | CHF206.17 Million |
Xlife Sciences AG Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Xlife Sciences AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CHF-903.00K | CHF-421.51K | CHF171.78K | CHF-4.61 Million | CHF-4.32 Million |
| Capital Expenditures | CHF372.20K | CHF12.09K | CHF41.08K | CHF80.16K | CHF1.21 Million |
| Free Cash Flow | CHF-1.28 Million | CHF-433.60K | CHF130.70K | CHF-4.69 Million | CHF-5.54 Million |
| Investing Cash Flow | — | CHF-4.00 Million | CHF-1.01 Million | CHF-1.68 Million | CHF-7.03 Million |
| Financing Cash Flow | — | CHF4.30 Million | CHF828.55K | CHF4.56 Million | CHF8.60 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CHF28.36 Million | CHF16.06 Million | CHF16.03 Million | CHF16.02 Million | CHF66.68K |
| Change in Cash | CHF304.44K | CHF-119.68K | CHF-2.33K | CHF-1.74 Million | CHF-2.75 Million |
Xlife Sciences AG Earnings History — EPS Actual vs. Analyst Estimates
Track Xlife Sciences AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 23, 2025 | -0.53 | — | — |
| Apr 25, 2025 | 4.46 | 0.00 | — |
| Sep 18, 2024 | 0.08 | 0.00 | — |
| Apr 20, 2023 | 2.36 | — | — |
| Sep 28, 2022 | -1.48 | 0.00 | — |
| Jun 30, 2022 | 7.07 | 0.00 | — |
| Aug 10, 2021 | 0.88 | 0.00 | — |
| Apr 26, 2021 | 2.42 | 0.00 | — |